Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 1103-1109

  Zojer, Niklas ^a   Kirchbacher, Klaus ^a   Vesely, Michael ^b   Hübl, Wolfgang ^c   Ludwig, Heinz ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c Central Laboratory   (Austria)

Author keywords

CD20; Myeloma; Phase II study; Plasma cells; Rituximab

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; IMMUNOGLOBULIN M; PARAPROTEIN; RITUXIMAB; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BACTEREMIA; BONE MARROW CELL; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RELAPSE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TARGETING; FEVER; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPOTENSION; INFECTION; MULTIPLE MYELOMA; MYELOMA CELL; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL; PLASMA CELL; POPULATION RESEARCH; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL; TREATMENT WITHDRAWAL; TUMOR GROWTH; WORLD HEALTH ORGANIZATION;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BONE MARROW CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN M; IMMUNOPHENOTYPING; MIDDLE AGED; MULTIPLE MYELOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746319879     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600564803     Document Type: Article

References (24)

1. Smith, M. (2003) Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance Oncogene, 22, pp. 7359-7368.
2. Coiffier, B and Lepage, E and Briere, J and Herbrecht, R and Tilly, H and Bouabdallah, R and et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma New Engl J Med, 346, pp. 235-242.
3. Robillard, N and Avet-Loiseau, H and Garand, R and Moreau, P and Pineau, D and Rapp, M and et al. (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma Blood, 102, pp. 1070-1071.
4. Bergsagel, P and Smith, A and Szczepek, A and Mant, M and Belch, A and Pilarski, L. (1995) In multiple myeloma, clonotypic B lymphocytes are detectable among CD19 + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain Blood, 85, pp. 436-447.
5. Pilarski, L and Giannakopoulos, N and Szczepek, A and Masellis, A and Mant, M and Belch, A. (2000) In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease Clin Cancer Res, 6, pp. 585-596.
6. Rasmussen, T. (2001) The presence of circulating clonal CD19 + cells in multiple myeloma Leuk Lymphoma, 42, pp. 1359-1366.
7. Matsui, W and Huff, C and Wang, Q and Malehorn, M and Barber, J and Tanhehco, Y and et al. (2004) Characterization of clonogenic multiple myeloma cells Blood, 103, pp. 2332-2336.
8. Szczepek, A and Seeberger, K and Wizniak, J and Mant, M and Belch, A and Pilarski, L. (1998) A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction Blood, 92, pp. 2844-2855.
9. Zojer, N and Schuster-Kolbe, J and Assmann, I and Ackermann, J and Strasser, K and Hübl, W and et al. (2002) Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19 + cells in patients with myeloma and monoclonal gammopathy of undetermined significance Br J Haematol, 117, pp. 852-859.
10. Blade, J and Samson, D and Reece, D and Apperley, J and Bjorkstrand, B and Gahrton, G and et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT Br J Haematol, 102, pp. 1115-1123.
11. Treon, S and Pilarski, L and Belch, A and Kelliher, A and Preffer, F and Shima, Y and et al. (2002) CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications J Immunother, 25, pp. 72-81.
12. Musto, P and Carella, A, Jr and Greco, M and Falcone, A and Sanpaolo, G and Bodenizza, C and et al. (2003) Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation Br J Haematol, 123, pp. 746-747.
13. Gemmel, C and Cremer, F and Weis, M and Witzens, M and Moldenhauer, G and Koniczek, K and et al. (2002) Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation Ann Hematol, 81, pp. 119-123.
14. Treon, S and Mitsiades, C and Mitsiades, N and Young, G and Doss, D and Schlossman, R and et al. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies J Immunother, 24, pp. 263-271.
15. Korte, W and Jost, C and Cogliatti, S and Hess, U and Cerny, T. (1999) Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy Ann Oncol, 10, pp. 1249-1250.
16. Hofer, S and Hunziker, S and Dirnhofer, S and Ludwig, C. (2003) Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma Br J Haematol, 122, pp. 690-691.
17. Wiestner, A and Cho, H and Asch, A and Michelis, M and Zeller, J and Peerschke, E and et al. (2002) Rituximab in the treatment of acquired factor VIII inhibitors Blood, 100, pp. 3426-3428.
18. Zecca, M and Nobili, B and Ramenghi, U and Perrotta, S and Amendola, G and Rosito, P and et al. (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children Blood, 101, pp. 3857-3861.
19. Edwards, J and Szczepanski, L and Szechinski, J and Filipowicz-Sosnowska, A and Emery, P and Close, D and et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis New Engl J Med, 350, pp. 2572-2581.
20. Gottenberg, J and Guillevin, L and Lambotte, O and Combe, B and Allanore, Y and Cantagrel, A and et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases Ann Rheum Dis, 64, pp. 913-920. for Club Rheumatismes et Inflammation (CRI)
21. Lim, S and Zhang, Y and Wang, Z and Varadarajan, R and Periman, P and Esler, W. (2004) Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency Blood, 103, pp. 1971-1972.
22. Ghobrial, I and Fonseca, R and Greipp, P and Blood, E and Rue, M and Vesole, D and et al. (2004) Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: An Eastern Cooperative Oncology Group Study Cancer, 101, pp. 2593-2598.
23. Treon, S and Branagan, A and Hunter, Z and Santos, D and Tournhilac, O and Anderson, K. (2004) Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia Ann Oncol, 15, pp. 1481-1483.
24. Rasmussen, T and Johnsen, H and Lodahl, M and Kuehl, M.(2005) In multiple myeloma 14q32 translocations are present in memory B cells but ras mutations are restricted to the plasma cell compartment. Sydney: Xth International Myeloma Workshop.